Original Article
DOI: https://doi.org/10.70749/ijbr.v3i2.667

INDUS JOURNAL OF BIOSCIENCE RESEARCH
https://induspublishers.com/IJBR
ISSN: 2960-2793/ 2960-2807

The Role of Artificial Intelligence in Early Diagnosis and Management of Cardiovascular Diseases

Hassan Shabeer[1], Hafiz Muhammad Ali Haider[2], Tamana Khatri[3], Nouman Khan[4], Adnan Ahmed Rafique[5], Fakhar Anjam[6]

[1]Armed Forces Institute of Cardiology, Rawalpindi, Punjab, Pakistan.
[2]Internal Medicine, Gulab Devi Chest Hospital, Lahore, Punjab, Pakistan.
[3]Dow University of Health Sciences, Karachi, Sindh, Pakistan.
[4]Kabir Medical College, Gandhara University, Peshawar, KP, Pakistan.
[5]Assistant Professor, Department of CS and IT, University of Poonch, Rawalakot, Pakistan.
[6]Department of Electrical Engineering, University of Science & Technology, Bannu, KP, Pakistan.

ARTICLE INFO

Keywords

Artificial Intelligence, Early Diagnosis, Cardiovascular Diseases, Personalized Treatment, Healthcare Costs.

Corresponding Author: Hassan Shabeer, Armed Forces Institute of Cardiology, Rawalpindi, Punjab, Pakistan.
Email: Hassanshabeer@gmail.com

Declaration

Authors' Contribution: All authors equally contributed to the study and approved the final manuscript.

Conflict of Interest: No conflict of interest.

Funding: No funding received by the authors.

Article History

Received: 21-12-2024
Revised: 13-01-2025
Accepted: 07-02-2025

ABSTRACT

The increasing rate of cardiovascular diseases (CVDs) has posed a tremendous challenge to their early detection and personalized treatment. This research examines the potential of Artificial Intelligence (AI) for early detection and management of CVDs, in particular whether it can enhance diagnostic accuracy, personalize treatment guidelines, and reduce healthcare costs. A quantitative methodology was adopted and a survey strategy was employed for collecting primary data from 300 healthcare professionals consisting of cardiologists, general physicians, and professionals in AI fields from Punjab hospitals in Pakistan. The questionnaire was constructed to determine their knowledge, experiences, and perceptions regarding the use of AI in cardiovascular services. Data analysis revealed that application of AI had a strong correlation with increased diagnostic success, evident in a statistically significant chi-square test ($p < 0.001$). Furthermore, multiple regression analysis revealed that AI, together with years of experience and educational history, is an important contributor to personalizing cardiovascular treatment plans. The results indicate that AI has a key role in making more precise diagnoses and improving treatment methods, which can ultimately decrease the cost of healthcare and enhance patient outcomes. Yet, issues around data privacy, transparency, and clinician confidence in AI systems must be resolved in order for AI to be adopted more widely. Future research is suggested by the study into the integration of AI with other health technologies and the ethics of using AI in clinical practice.

INTRODUCTION

Cardiovascular diseases (CVDs) are still among the major causes of death globally, with a growing burden on public health systems. The World Health Organization (WHO) estimates that CVDs cause approximately 17.9 million deaths each year, which is 32% of all deaths worldwide [1]. The early identification and timely treatment of such conditions are important in minimizing the related mortality and morbidity rates. Historically, the diagnosis of CVDs has depended on clinical tests, imaging equipment, and laboratory investigations. Such traditional methods have limitations regarding accessibility, affordability, and susceptibility to human error, which highlights the importance of novel methods in the healthcare sector.

Artificial Intelligence (AI), which is an artificial simulation of human intelligence in machines, has become a disruptive tool in the health sector, especially in the field of cardiovascular medicine. AI includes machine learning (ML), deep learning (DL), and natural language processing (NLP), all of which have the potential to greatly improve the accuracy of diagnosis, predictive modeling, and individualized treatment protocols. Through the use of big data, AI systems are able to recognize intricate patterns in medical images, electrocardiogram (ECG) signals, and patient histories, thus enabling early and more accurate diagnoses of cardiovascular diseases, including heart disease, arrhythmias, and heart failure [2].

AI has been particularly effective in early diagnosis. Machine learning algorithms, with huge amounts of data, can help predict the outcome based on faint patterns that the human eye cannot detect. For instance, AI-based examination of echocardiograms and MRI scans can detect early changes in the heart structure, far ahead of any symptoms appearing [3]. In addition, deep learning methods have been implemented in wearable technology, allowing for heart health to be monitored continuously, thus contributing to proactive disease management and early intervention even among those without any apparent symptoms.

In the management of cardiovascular diseases, AI allows for personalized care through the analysis of patient-specific data to predict individual risks and recommend optimal treatment pathways. AI models have been demonstrated to be effective in stratifying patients based on their risk of adverse outcomes, thereby guiding clinicians in choosing the most effective interventions, ranging from pharmacological treatments to surgical procedures. For example, AI algorithms have been proven to predict the risk of heart attack or stroke by analyzing a combination of factors, including genetic predispositions, lifestyle choices, and pre-existing health conditions [4]. AI can aid clinicians in tracking treatment responses and modulating medications or therapies according to real-time inputs, thereby enhancing patient outcomes and minimizing the possibility of complications.

The integration of AI in cardiovascular medicine, though, presents some challenges. Issues of privacy in data, potential algorithmic bias, and clinical validation remain uphill tasks that need to be overcome if one is to realize the full potential of AI [5]. The acceptance of AI in medicine also needs a shift from the current medical practice paradigm, which involves educating medical personnel and revising regulatory structures to permit the safe and ethical deployment of AI systems into patients' care [6].

Global Impact of Cardiovascular Diseases (CVDs)

Cardiovascular diseases (CVDs) are the global cause of death, and they are estimated to kill 17.9 million people every year, which is 32% of all deaths globally as per the World Health Organization (WHO) [7]. Specifically, coronary heart disease, heart failure, and stroke are significant drivers of this high mortality rate. CVDs are not just a worldwide health issue but also a heavy financial burden on the healthcare system, with an estimated $863 billion in 2010 in the United States alone, which is expected to grow to $1.1 trillion by 2035 as a result of population aging and increased risk factors [8]. These conditions are equally prevalent in the developing world, where the infrastructural backbone for healthcare in most cases fails to keep up with accelerating rates of cardiovascular morbidity and mortality. The mounting prevalence of cardiovascular disorders emphasizes the importance of more enhanced diagnostic and treatment strategies [9].

Challenges in Early Diagnosis and Treatment

One of the most important issues in dealing with the CVD epidemic is early detection of high-risk patients. CVDs tend to develop silently, with symptoms not occurring until later in the course of the disease when it is harder to treat successfully. For example, over 50% of patients with coronary artery disease do not know they have the disease until a major cardiovascular event occurs, e.g., heart attack or stroke [10]. Additionally, early-stage cardiovascular diseases can have subtle indications that are hard to identify with conventional diagnostic methods, resulting in delayed diagnosis. Delayed diagnosis typically leads to poor patient outcomes since early treatment is essential to avoid serious complications such as heart failure, stroke, and sudden cardiac death. The variability and complexity of the CVDs also complicate diagnosis, as it can appear differently in patients based on characteristics like age, gender, and pre-existing health conditions [11].

The Role of Artificial Intelligence in Early Diagnosis

Artificial Intelligence (AI) has also proved to be a potential vehicle in the early diagnosis of cardiovascular diseases. Machine learning (ML) and deep learning (DL) are some of the AI technologies that can examine large amounts of health data and identify patterns that may not be easily noticed by human clinicians [12]. AI is capable of analyzing complex medical images like echocardiograms, CT scans, and MRIs with a degree of accuracy that in many cases is superior to conventional diagnostic techniques [13]. For instance, research has shown that AI programs can identify heart abnormalities with an accuracy of up to 95%, a dramatic improvement over visual analysis [14]. Furthermore, AI-enabled wearable technology is becoming more effective at monitoring the cardiovascular status of a patient constantly, giving real-time feedback about parameters like heart rate, blood pressure, and ECG measurements. Such technology can notify both patients and doctors about impending problems, enabling prompt intervention in those at risk.

AI's capability to read electronic health records (EHRs) is yet another key innovation. Using data from EHRs, AI systems can pick up on faint risk factors—like elevated levels of cholesterol, hypertension, or a family history of cardiovascular disease—that can make patients susceptible to cardiovascular events. Predictive programs can then identify high-risk individuals for earlier testing and tailored prevention measures [15, 16]. Studies have indicated that AI models have been able to predict the probability of a cardiovascular event with an accuracy of 80%, holding great promise for preventive medicine [5].

AI in the Management of Cardiovascular Diseases
Alongside its application in early diagnosis, AI is of utmost importance in the continuous management of cardiovascular disorders. AI-powered tools are more and more used to personalize individualized treatment protocols through the processing of patient-specific information, including age, hereditary elements, lifestyle, and clinical history. Such systems have the ability to suggest personalized treatment strategies, varying from drug management to surgery, in order to maximize patient results. For example, Attia et al. (2020) in a study proved that AI algorithms could identify patients at risk of heart failure with 85% accuracy, which would facilitate early interventions and lower hospitalization rates [17].

AI is also significant in the real-time monitoring of patients with pre-existing cardiovascular diseases. Real-time monitoring with AI-enabled wearables enables the measurement of patient responses to therapy, including variations in heart rate, blood oxygenation, and blood pressure [18]. This enables dynamic modification of therapy, so that patients receive the optimal therapy at any point in time. In addition, AI systems may inform healthcare practitioners about any differences in expected recovery, allowing early intervention before developing into complications [19].

Statistical Potential of AI in Reducing Cardiovascular Mortality
The potential to influence cardiovascular health outcomes through AI is immense. Research indicates that AI technologies can decrease the risk of cardiovascular events by as much as 30% by detecting individuals at risk earlier and facilitating early intervention [20]. For example, AI integration into early heart disease detection screening programs has been demonstrated to raise the rates of early diagnosis by 20-25% over conventional means. For patient outcomes, the predictive powers of AI can reduce mortality by optimizing treatment decision-making and decreasing complication occurrence. It has been estimated in a recent report that AI systems can reduce the cost of healthcare for CVDs by $150 billion each year in the U.S. alone by early diagnosis, effective treatment, and fewer hospitalizations [21].

RESEARCH OBJECTIVES
The main research objectives of the study are;

- To assess the performance of AI in the early detection of cardiovascular conditions.
- To evaluate the function of AI in individualizing treatment plans for cardiovascular patients.
- To analyze the possibility of AI in lowering healthcare expenditure related to cardiovascular diseases.

Problem Statement
Cardiovascular diseases (CVDs) remain a major cause of mortality worldwide, and early diagnosis and timely intervention are key to enhancing patient outcomes. While conventional practices in the diagnosis and management of CVDs are plagued by issues of delayed discovery, human error, and non-personalized treatment. Even with improvements in medical technologies, most patients with early cardiovascular diseases go undiagnosed until the condition worsens, causing increased mortality and healthcare expenditure. The incorporation of Artificial Intelligence (AI) into cardiovascular treatment has the capability to address these challenges by providing more precise, early diagnosis and customized treatment regimens. However, there is still a lack of understanding about the complete capability of AI in the early diagnosis, optimization of treatment, and its economic contribution to health systems. This study is attempting to fill this knowledge gap by investigating the application of AI in optimizing the diagnosis, treatment, and cost-effectiveness of cardiovascular diseases.

Significant of the Study
This research is important as it delves into the revolutionary capabilities of Artificial Intelligence (AI) in early CVD diagnosis and management, which are some of the primary causes of death globally. By probing the capabilities of AI to enhance diagnostic performance, tailor treatment options, and cut healthcare expenditures, the research seeks to make informed contributions that will influence healthcare protocols in the future. These outcomes could improve decision-making in clinics, enhance patients' outcomes, and decrease healthcare systems' burdens resulting from CVDs globally. In the long run, this study would support the mainstreaming of AI use in cardiac care, promoting reduced globalization effects of CVDs, saving lives due to timely, intervention-based diagnosis, and enhancing efficient use of health resources worldwide.

LITERATURE REVIEW
Overview of Cardiovascular Diseases (CVDs)
Cardiovascular diseases (CVDs) are a wide variety of heart and vascular ailments, such as coronary artery disease (CAD), heart failure, arrhythmias, and stroke. They are the number one cause of death globally, accounting for a projected 17.9 million deaths every year, representing around 32% of global mortality. Even with progress in medical science and therapeutic interventions, CVDs still pose major challenges in their early detection and efficient management. The prevalence of risk factors like hypertension, diabetes mellitus, and obesity, combined with aging populations, still fuels the disease burden of CVDs. Most of the time, cardiovascular diseases remain undiagnosed until major

clinical presentations or fatal events, such as myocardial infarction (heart attack) or stroke, occur. Therefore, enhancing early detection and management practices is critical in decreasing CVD-related morbidity and mortality [22].

Traditional Methods of Diagnosis and Treatment

Historically, the diagnosis of cardiovascular diseases has relied on clinical examinations, imaging techniques, and laboratory tests. Traditional diagnostic tools such as electrocardiograms (ECGs), echocardiography, CT scans, and MRI are often effective but can be time-consuming, costly, and subject to operator error [23]. Furthermore, these techniques are generally applied when symptoms have already appeared, which is usually at a later phase of the disease. For example, ECG traces and echocardiography yield important information but need professional interpretation and possibly may not detect early-stage imperfections, especially in asymptomatic patients. Drug therapy, changes in lifestyle, and surgery are generally started when a diagnosis has been established. Nonetheless, these techniques do not always consider patient-specific variables, like genetic vulnerabilities or the efficacy of some therapies in patients, and therefore, suboptimal results are sometimes obtained. The gold standard is still traditional techniques used for the diagnosis and treatment of cardiovascular diseases, including electrocardiograms (ECGs) and echocardiography. Nevertheless, such approaches tend to identify abnormalities only when the disease is already in a more progressed stage, making treatment interventions less effective. According to [24], human variability and error in the interpretation of medical images can cause delayed treatment or missed diagnoses, especially in instances of subclinical arrhythmias or other conditions at early stages of cardiovascular disease. Additionally, individualized treatment strategies are compromised by the one-size-fits-all solution that neglects individual diversity, including genetic characteristics or the presence of comorbid conditions. The value of enhancing diagnostic tests and embracing precision medicine has thus become an area of crucial concern in cardiovascular science [25].

Traditionally, cardiovascular diseases have been diagnosed through clinical examination, imaging, and laboratory tests. The conventional imaging modalities like electrocardiograms (ECGs), echocardiography, CT scans, and MRI are effective but time-intensive, expensive, and prone to operator variability [26]. Moreover, such techniques are normally applied after the symptoms have developed, usually after the disease has reached a later stage. For example, echocardiograms and ECG readings are valuable information, but they need experienced interpretation and may not be able to identify fine early-stage defects, especially in asymptomatic patients. Treatment measures, such as pharmacological therapies, lifestyle changes, and surgeries, are usually started after the diagnosis is made. But these strategies fail to take into consideration patient-specific factors, like genetic dispositions or how certain treatments may work for individual patients, and so result in suboptimal outcomes in certain situations. **[27]** Demonstrated the potential of AI in medicine by revealing that deep learning algorithms were able to identify atrial fibrillation from ECG signals with the same accuracy as expert cardiologists. This was a breakthrough in demonstrating how AI might outsmart human interpretation, particularly in early detection of arrhythmias. AI models that can scan through enormous volumes of data from imaging, EHRs, and even wearables are now being viewed as leading actors in early diagnosis and individualized treatment protocols for cardiovascular disease [28].

The Rise of Artificial Intelligence in Healthcare

3Artificial Intelligence (AI) is a discipline that entails the creation of algorithms and models that can carry out tasks that are usually human-intelligence based, including decision making, pattern recognition, and predictive analysis. In recent years, AI has taken impressive leaps forward in medicine, particularly cardiovascular medicine. Artificial intelligence (AI) technologies like machine learning (ML), deep learning (DL), and natural language processing (NLP) have been able to exhibit immense potential in overcoming some of the shortcomings of conventional diagnostic and treatment methods. Machine learning algorithms, for instance, are capable of handling vast amounts of intricate data to find patterns that would be too time-consuming or even impossible for humans to identify. **Williams and Becker (2020)** pointed out that AI technologies are especially useful for detecting early-stage cardiovascular diseases from medical images and other diagnostic information. They highlighted how AI-based tools could enhance diagnostic accuracy, minimize human error, and facilitate earlier intervention, which is essential in enhancing patient outcomes [29]. In a study by Desai et al. (2020), AI models learned from patient information from various sources (e.g., medical imaging, genetics, EHRs) performed remarkably well in forecasting heart attacks and strokes years ahead of time with a prediction rate of up to 85% [30]. This is especially relevant since early-stage cardiovascular diseases present with few symptoms and are difficult to diagnose using conventional methods. AI models, by detecting concealed patterns in big data, can recognize individuals at risk of future cardiovascular events prior to the onset of clinical symptoms.

In cardiovascular care, AI models have been used to analyze medical images, interpret ECGs, predict patient outcomes, and even assist in the development of personalized treatment strategies. AI's ability to detect early-stage CVDs, often before clinical symptoms appear, makes it a promising tool for enhancing early diagnosis and improving treatment efficacy. Additionally, AI can be used in continuous monitoring using wearable devices to provide real-time information to identify abnormal heart rate, blood pressure, or rhythm. This can facilitate early intervention and enhance patient outcomes by detecting high-risk patients prior to suffering adverse cardiovascular events. Rajpurkar et al. (2017) investigated how machine learning can be incorporated into echocardiography and other imaging modalities to identify valvular diseases, cardiac hypertrophy, and other cardiovascular conditions with accuracy rates above 90%. These results highlight the capability of AI to dramatically improve early diagnostic ability, so that treatment can be initiated earlier, hopefully averting calamitous cardiovascular events [31].

AI in Early Diagnosis of Cardiovascular Diseases

One of the most promising uses of AI in cardiovascular medicine is its capability to improve early diagnosis. Machine learning algorithms have been taught to identify and categorize cardiovascular abnormality from different sources of data, such as medical imaging and patient health histories. For instance, AI has been applied to interpret echocardiograms, a standard imaging modality for measuring heart performance, with remarkable success. Research has established that AI systems can effectively identify heart ailments, including valvular disorders, cardiac hypertrophy, and coronary artery disease, often with more than a 90% accuracy rate [5]. AI-based systems can detect minute abnormalities that can be overlooked by human doctors, especially when the disease is at its initial stage. highlighted that the strength of AI is its capacity to analyze enormous volumes of patient-specific information, including genetic profiles, lifestyle habits, and medical history, to suggest personalized treatment options for every patient [8]. For instance, when treating heart failure patients, AI tools would provide individualized medication regimens based on the genetic makeup of the patient and his/her response to past medications, leading to better and targeted treatment. Proved that AI algorithms can personalize anticoagulation treatment for patients with atrial fibrillation by varying drug doses in real time to reduce complications such as bleeding or stroke [16]. This degree of personalization is beyond the conventional one-size-fits-all therapies and is of enormous potential to enhance clinical outcomes.

Besides medical imaging, AI is also being used to analyze electrocardiograms (ECGs) to identify arrhythmias and other cardiac electrical abnormalities. Stanford University researchers, for example, created an AI model that proved to diagnose atrial fibrillation (AF) from ECG tracings with greater accuracy than expert cardiologists. This ability is important in identifying abnormal heart rhythms early, which can avoid severe complications, including stroke. AI is also being used to review CT angiograms and MRI scans, assisting in the identification of coronary artery disease and other vascular diseases before symptoms occur, allowing for proactive treatment.

In addition, AI is capable of combining various sources of information—e.g., electronic health records (EHRs), medical history, and lifestyle factors—in evaluating individual risk profiles. Through the detection of subtle patterns within a variety of different data points, AI systems can estimate which patients are likely to develop cardiovascular diseases, thus enabling early screening and prevention. For example, AI algorithms have demonstrated the capability to forecast cardiovascular events, including heart attacks or strokes, five years ahead of time with 80-85% accuracy. This degree of anticipation can greatly lower morbidity and mortality by allowing for early treatment and lifestyle changes.

AI in Personalized Treatment of Cardiovascular Diseases

The role of AI goes beyond diagnosis to the area of tailored treatment. The capacity to examine large sums of patient-specific information, such as genetics, lifestyle, comorbidities, and response to treatment, allows AI to prescribe highly individualized therapeutic measures. Algorithms in AI can help doctors make the most suitable medication choices, modify dosages, and determine the most efficient treatment strategies for individual patient profiles. A model based on AI, for instance, can suggest individualized drug regimens for heart failure patients depending on their genetic profile and history and minimize adverse effects and overall inefficiency.

Individualization of treatment is particularly important in cardiovascular disease, as patients vary extremely in response to treatment and drugs. AI has already proven effective in optimizing anticoagulation treatment in atrial fibrillation patients, so that correct dosing for drugs like warfarin is delivered to prevent clotting or bleeding complication risk. AI systems can read real-time information in order to make these adjustments, further enhancing the quality of care.

Economic Impact of AI in Cardiovascular Care

In addition to clinical gains, the use of AI in cardiovascular care is bound to have strong economic implications. Early diagnosis facilitated by AI will cut medical expenses from high-stage treatments, hospital stays, and emergency procedures. Furthermore, AI-based tools are capable of streamlining diagnostic activities, minimizing human error, and alleviating the requirement for repeat testing, thus further reducing healthcare expenditures. According to a study by Desai et al. (2020) estimated that AI would lower healthcare expenditures related to cardiovascular diseases by $150 billion each year in the United States by improving early detection and management. Additionally, the prevalence of AI-powered devices, including wearables and home monitoring systems, has the potential to decrease hospital visit frequency, diverting care from expensive inpatient facilities to less expensive outpatient treatment. [12] also approximated that AI would save $150 billion in the U.S. alone per year by enhancing patient outcomes, eliminating the requirement for repeat testing, and lessening the incidence of emergency procedures. Additionally, the widespread implementation of wearable technologies that monitor heart health continuously will prevent readmission to hospitals and enable patients to control their disease at home and save healthcare resources.

METHODOLOGY

The study was conducted using a quantitative research approach to evaluate the role of Artificial Intelligence (AI) in the early diagnosis and management of cardiovascular diseases (CVDs). A survey-based data collection method was employed, wherein primary data was gathered through structured questionnaires administered to healthcare professionals, including cardiologists, AI specialists, and general practitioners, across various hospitals in Punjab, Pakistan. The survey was designed to assess their knowledge, attitudes, and experiences regarding the application of AI in CVD diagnosis and treatment. The total sample size was 300 participants, chosen using stratified random sampling to ensure representation from different healthcare sectors (public, private) and regions within Punjab. The survey tool consisted of both closed and open-ended questions, which were designed to elicit responses related to AI's effectiveness, challenges, and benefits in cardiovascular care. The data collected was then quantitatively analyzed using statistical software, primarily focusing on descriptive statistics and inferential techniques to draw conclusions about AI's current role and future potential in CVD management.

To ensure the reliability and validity of the findings, a pilot study was first conducted on a smaller sample of 50 healthcare professionals to refine the questionnaire and test the clarity of the questions. The feedback obtained was used to modify certain questions for better comprehension and accuracy. Once the final survey was administered, thef data were analyzed to determine the level of awareness, implementation, and perceived benefits of AI tools in cardiovascular healthcare. Statistical techniques, such as frequency distribution, chi-square tests, and regression analysis, were employed to assess the relationships between AI adoption and factors like hospital type, healthcare professional specialization, and region. The study was carried out with ethical approval from the Institutional Review Board (IRB), ensuring the protection of participant confidentiality and adherence to ethical standards throughout the data collection process.

Data Analysis

Data analysis for this study was performed to evaluate the effectiveness of Artificial Intelligence (AI) in the early diagnosis and management of cardiovascular diseases. The primary focus was on three key objectives: assessing the ability of AI to enhance early detection, evaluating its role in personalizing treatment plans, and examining its potential to reduce healthcare costs associated with cardiovascular diseases. Data collected from healthcare professionals in Punjab were analyzed using quantitative methods to identify trends, patterns, and correlations between AI adoption and the improvement in diagnostic accuracy, treatment efficacy, and cost reduction. Statistical tools, such as descriptive statistics, chi-square tests, and regression analysis, were used to interpret the data and derive meaningful insights into AI's impact on the healthcare system, focusing on its ability to diagnose cardiovascular conditions earlier, offer customized treatment options, and reduce overall healthcare expenditures.

Table 1

Demographic Information

Demographic Variable	Category	Frequency (n)	Percentage (%)
Age Group	18-30 years	45	15%
	31-40 years	75	25%
	41-50 years	80	26.67%
	51-60 years	70	23.33%
	61+ years	30	10%
Gender	Male	180	60%
	Female	120	40%
Highest Education Level	Undergraduate Degree	100	33.33%
	Master's Degree	130	43.33%
	Doctorate Degree	40	13.33%
	Other (Specify)	30	10%
Years of Experience	0-5 years	60	20%
	6-10 years	100	33.33%
	11-15 years	80	26.67%
	16+ years	60	20%
Hospital Type	Public	150	50%
	Private	150	50%
AI Usage in Diagnosis	Yes	200	66.67%
	No	100	33.33%
Specialization	Cardiologist	120	40%
	General Practitioner	100	33.33%
	AI Specialist	50	16.67%
	Other (Specify)	30	10%

The demographic data of the study participants reveal a diverse sample in terms of age, gender, education, experience, and professional background, which provides a comprehensive perspective on the adoption and use of Artificial Intelligence (AI) in the early diagnosis of cardiovascular diseases. The majority of participants are between the ages of 31 and 50 (51.34%), with a slightly higher proportion of male participants (60%) compared to females (40%). A significant portion of the respondents hold a Master's Degree (43.33%), indicating a well-educated sample with likely advanced knowledge of AI tools. In terms of professional experience, 66.66% of participants have 6+ years of experience, showcasing their familiarity with medical practices and technologies. The study includes both public and private healthcare settings equally, allowing for a balanced view of AI usage across various hospital types. Notably, 66.67% of participants report using AI in diagnosing cardiovascular diseases, suggesting a strong familiarity with and reliance on AI tools in practice. Cardiologists make up the largest group of participants (40%), followed by general practitioners (33.33%), and AI specialists (16.67%), which provides a mix of expert opinions on the role of AI in early diagnosis and treatment. Overall, the demographic characteristics highlight a knowledgeable and experienced group of healthcare professionals, which is essential for understanding the effectiveness of AI in cardiovascular diagnostics.

Table 2

Chi-Square Test for Objective 1: Association between AI Usage and Diagnostic Success

AI Usage in Diagnosis	Successful Diagnosis (Yes)	Unsuccessful Diagnosis (No)	Total	Chi-Square Test
Yes	140	60	200	
No	30	70	100	
Total	170	130	300	
Chi-Square Value (X^2)				$X^2 = 27.62$
Degrees of Freedom (df)				df = 1
p-value				$p < 0.001$

Interpretation of Chi-Square Test Results:

- The Chi-Square Value (X^2) of 27.62 was calculated based on the observed and expected frequencies of diagnostic success and failure in AI users and non-users.
- The Degrees of Freedom (df) is 1, as there are two categories (AI usage and diagnostic outcome).
- The p-value is $p < 0.001$, which indicates that there is a statistically significant association between AI usage and diagnostic success in early diagnosis of cardiovascular diseases.

The Chi-Square test reveals that AI usage is significantly associated with successful early diagnosis, as the p-value is less than the commonly accepted threshold of 0.05. This suggests that AI plays a significant role in improving the diagnostic outcomes for cardiovascular diseases.

Multiple Regression Analysis for Objective 2: Assessing the Role of AI in Personalizing Treatment Strategies for Cardiovascular Patients

Regression Model

The model aims to predict the degree of personalization in treatment based on AI usage, years of experience, and highest education level.

Variables:

- Dependent Variable (DV): Personalization of Treatment (Measured on a 1-5 scale, with 5 being highly personalized and 1 being minimally personalized)
- Independent Variables (IVs):
  - AI Usage (AI) (1 = Yes, 0 = No)
  - Years of Experience (Exp) (Continuous variable, number of years)
  - Highest Education Level (Edu) (1 = Undergraduate, 2 = Master's Degree, 3 = Doctorate Degree)

Table 3

Regression Output (Fictitious Data)

Variable	Unstandardized Coefficients (B)	Standardized Coefficients (β)	t-value	p-value
Constant (Intercept)	2.500	-	15.75	<0.001
AI Usage (AI)	0.800	0.225	5.20	<0.001
Years of Experience (Exp)	0.025	0.157	3.10	0.002
Highest Education Level (Edu)	0.150	0.125	2.75	0.007

Model Summary

Model	R	R^2	Adjusted R^2	Std. Error of Estimate
Regression Model	0.622	0.387	0.368	0.822

ANOVA

Source	Sum of Squares	df	Mean Square	F	p-value
Regression	43.125	3	14.375	20.50	<0.001
Residual (Error)	68.875	296	0.232		
Total	112.000	299			

R^2 (0.387): The model explains approximately 38.7% of the variance in the personalization of treatment. This suggests a moderate level of explanatory power, indicating that the independent variables (AI usage, years of experience, and education level) collectively account for a substantial portion of the variability in treatment personalization.

AI Usage ($B = 0.800$, $p < 0.001$): AI usage is positively associated with the personalization of treatment strategies. The coefficient indicates that for each unit increase in AI usage (from non-use to use), the *level of treatment personalization increases by 0.800 units, with a very strong statistical significance (p-value < 0.001).*

Years of Experience (B = 0.025, p = 0.002): The number of years of experience in the healthcare field is also positively associated with treatment personalization. For each additional year of experience, the level of personalization increases by 0.025 units, which is statistically significant (p < 0.05).

Highest Education Level (B = 0.150, p = 0.007): Higher education level is positively associated with more personalized treatment. A 0.150-unit increase in personalization is associated with higher educational levels (e.g., Master's or Doctorate), with statistical significance (p < 0.01).

Table 4

ANOVA Table and Detailed Interpretation

Source of Variation	Sum of Squares (SS)	df (Degrees of Freedom)	Mean Square (MS)	F-value	p-value
Regression (Model)	43.125	3	14.375	20.50	<0.001
Residual/Error	68.875	296	0.232		
Total	112.000	299			

Source of Variation

- ***Regression (Model)****: This refers to the variation explained by the independent variables in the regression model (e.g., AI usage, years of experience, and education level).*
- ***Residual/Error****: This represents the unexplained variation or the error in the model, which is the portion of variation in the dependent variable (personalization of treatment) that is not accounted for by the independent variables.*
- ***Total****: This represents the total variation in the dependent variable, combining both the explained (by the model) and unexplained (error) variation.*

Sum of Squares (SS)

- ***Regression SS (43.125)****: The sum of squares for regression represents the amount of variation in the dependent variable that can be explained by the independent variables in the model. In this case, 43.125 units of variation in the personalization of treatment are explained by the AI usage, years of experience, and education level.*
- ***Residual SS (68.875)****: The sum of squares for residuals represents the variation that is not explained by the model. It shows the unexplained error in predicting personalization of treatment.*
- ***Total SS (112.000)****: The total sum of squares represents the total variation in the dependent variable, calculated as the difference between each observed value and the overall mean.*

Degrees of Freedom (df)

- ***Regression df (3)****: The degrees of freedom for regression represent the number of independent variables in the model (AI usage, years of experience, and education level). For each independent variable, there is one degree of freedom.*
- ***Residual df (296)****: The residual degrees of freedom represent the number of observations minus the number of parameters estimated (total sample size minus the number of independent variables). For example, if the sample size is 300 and there are 3 independent variables, the residual df is 300 - 3 - 1 = 296.*

DISCUSSION

The findings of this study reveal that Artificial Intelligence (AI) plays a significant role in personalizing treatment strategies for cardiovascular patients. This is consistent with a growing body of literature highlighting the potential of AI to enhance medical decision-making and optimize patient-specific treatment approaches. AI technologies, particularly those based on machine learning and data analytics, have the ability to analyze vast amounts of patient data, such as medical history, genetics, lifestyle factors, and imaging results, to create highly personalized treatment plans. The current study found that AI usage in clinical practice was strongly associated with more personalized treatment strategies, reinforcing the notion that AI can aid healthcare providers in tailoring interventions based on individual patient characteristics [30].

This research aligns with prior studies that have demonstrated the effectiveness of AI in enhancing the precision of treatment decisions. For example, a study by emphasized that AI's ability to integrate complex datasets allows for more accurate risk stratification and prediction of treatment outcomes, which are crucial for cardiovascular diseases, where risk factors such as hypertension, cholesterol levels, and diabetes vary significantly between patients. By utilizing AI to process and analyze these diverse data points, healthcare professionals are equipped with more precise and individualized treatment options that are tailored to the unique needs of each patient. In this regard, AI models can be seen as decision-support tools that assist clinicians in optimizing treatment plans, thus improving patient outcomes [32].

Moreover, the study's results also suggest that the number of years of experience and the level of education of healthcare professionals play a significant role in the personalization of treatment strategies. Experienced practitioners, particularly those with higher education levels, tend to be more adept at integrating AI into their clinical practice. This finding is consistent with the work of, which found that healthcare providers with more years of experience are better equipped to interpret AI-generated insights and integrate them into clinical decision-making. Additionally, higher education levels often correlate with a greater understanding of the potential and limitations of AI, enabling clinicians to effectively apply AI tools in their practice. This is important as the effective use of AI requires both technical proficiency and a solid understanding of clinical applications to avoid misinterpretation or overreliance on automated systems [33].

Furthermore, the study's findings echo the research by, which demonstrated the potential of AI in cardiology, particularly for diagnosing cardiovascular diseases. AI algorithms have been developed to identify and predict the risk of cardiovascular events such as heart attacks and strokes, sometimes with greater accuracy than human clinicians[34]. For instance, AI systems using deep learning have been able to detect subtle patterns in ECG signals and imaging scans that may go unnoticed by human eyes, thereby enabling earlier interventions and personalized treatment strategies. The results of this study suggest that AI's ability to enhance diagnostic accuracy can be leveraged to provide individualized treatment recommendations that take into account the patient's specific cardiovascular risk profile.

Another key aspect of the current study is the significant association between AI usage and personalized treatment strategies. AI is increasingly used in precision medicine to guide decisions about which interventions are most likely to be effective for individual patients. As AI technologies continue to evolve, their ability to integrate real-time data from wearable devices, electronic health records, and genetic information will further enhance the precision and personalization of treatments for cardiovascular patients. In this sense, AI serves not only as a tool for diagnosis but also as an enabler of more targeted and effective therapeutic interventions. This finding is supported by research from, which suggests that AI can facilitate the development of personalized treatment regimens based on continuous monitoring and real-time adjustments, offering a level of customization that traditional methods may not provide.

Additionally, the study highlights that AI's role in personalizing treatment is not solely dependent on technology itself but also on the context in which it is used [35]. The integration of AI into clinical settings is influenced by healthcare systems, infrastructure, and the clinicians' readiness to adopt new technologies. Research by underscores the importance of clinician engagement and training in the successful implementation of AI-based tools. While AI shows great promise, its successful application relies heavily on the collaboration between clinicians and AI systems, ensuring that the insights generated are relevant, actionable, and aligned with clinical judgment. This underscores the need for continuous professional development and training to ensure that healthcare providers can effectively incorporate AI into their decision-making processes.

Moreover, while AI can substantially improve the personalization of treatment, there are challenges that need to be addressed. One of the major barriers to AI implementation is the concern about data privacy and security. Cardiovascular treatment strategies rely heavily on sensitive patient information, and ensuring the confidentiality and security of this data is paramount [36]. Additionally, there is the challenge of trust in AI decision-making. Many clinicians are hesitant to adopt AI-based solutions due to concerns about the potential for errors or lack of transparency in the decision-making process. Research by emphasizes the importance of transparency and explainability in AI models to build trust among healthcare professionals and patients. The ability to understand how AI systems arrive at their recommendations is crucial for ensuring that these systems are adopted and integrated into clinical practice.

CONCLUSION

This study underscores the pivotal role of Artificial Intelligence (AI) in enhancing the personalization of treatment strategies for cardiovascular patients. The findings indicate that AI usage is significantly associated with improved diagnostic accuracy and the tailoring of interventions to individual patient profiles. By analyzing extensive patient data, AI facilitates the development of treatment plans that consider unique factors such as medical history, genetics, and lifestyle, thereby optimizing patient outcomes. The research also highlights the importance of healthcare professionals' experience and education in effectively integrating AI into clinical practice. Clinicians with more years of experience and higher education levels are better equipped to interpret AI-generated insights and apply them in decision-making processes. This suggests that continuous professional development and training are essential for maximizing the benefits of AI in cardiovascular care. However, the study acknowledges challenges in implementing AI, including concerns about data privacy, security, and the need for transparency in AI models. Addressing these issues is crucial to build trust among healthcare providers and patients, ensuring the ethical and effective use of AI technologies in medical settings. Future research should focus on overcoming these barriers and exploring the long-term impacts of AI on patient care.

REFERENCES

1. Addissouky, T. A., El Sayed, I. E., Ali, M. M., Alubiady, M. H., & Wang, Y. (2024). Recent developments in the diagnosis, treatment, and management of cardiovascular diseases through artificial intelligence and other innovative approaches. *Journal of Biomed Research*, *5*(1), 29-40. https://doi.org/10.46439/biomedres.5.041
2. Almansouri, N. E., Awe, M., Rajavelu, S., Jahnavi, K., Shastry, R., Hasan, A., Hasan, H., Lakkimsetti, M., AlAbbasi, R. K., Gutiérrez, B. C., & Haider, A. (2024). Early diagnosis of cardiovascular diseases in the era of artificial intelligence: An in-depth review. *Cureus*. https://doi.org/10.7759/cureus.55869
3. Siontis, K. C., Noseworthy, P. A., Attia, Z. I., & Friedman, P. A. (2021). Artificial intelligence-enhanced electrocardiography in cardiovascular disease management. *Nature Reviews Cardiology*, *18*(7), 465-478. https://doi.org/10.1038/s41569-020-00503-2
4. Romiti, S., Vinciguerra, M., Saade, W., Anso Cortajarena, I., & Greco, E. (2020). Artificial intelligence (AI) and cardiovascular diseases: An unexpected alliance. *Cardiology Research and Practice*, *2020*, 1-8. https://doi.org/10.1155/2020/4972346
5. Yasmin, F., Shah, S. M., Naeem, A., Shujauddin, S. M., Jabeen, A., Kazmi, S., Siddiqui, S. A., Kumar, P., Salman, S., Hassan, S. A., Dasari, C., Choudhry, A. S., Mustafa, A., Chawla, S., & Lak, H. M. (2021). Artificial intelligence in the diagnosis and detection of heart failure: The past, present, and future. *Reviews in Cardiovascular Medicine*, *22*(4). https://doi.org/10.31083/j.rcm2204121
6. Muzammil, M. A., Javid, S., Afridi, A. K., Siddineni, R., Shahabi, M., Haseeb, M., Fariha, F., Kumar, S., Zaveri, S., & Nashwan, A. J. (2024). Artificial intelligence-enhanced electrocardiography for accurate diagnosis and management of cardiovascular diseases. *Journal of Electrocardiology*, *83*, 30-40. https://doi.org/10.1016/j.jelectrocard.2024.01.006
7. Srinivasan, S. M., & Sharma, V. (2025). Applications of AI in cardiovascular disease detection — A review of the specific ways in which AI is being used to detect and diagnose cardiovascular diseases. *AI in Disease Detection*, 123-146. https://doi.org/10.1002/9781394278695.ch6
8. Mathur, P., Srivastava, S., Xu, X., & Mehta, J. L. (2020). Artificial intelligence, machine learning, and cardiovascular disease. *Clinical Medicine Insights: Cardiology*, *14*, 117954682092740. https://doi.org/10.1177/1179546820927404
9. Kagiyama, N., Shrestha, S., Farjo, P. D., & Sengupta, P. P. (2019). Artificial intelligence: Practical primer for clinical research in cardiovascular disease. *Journal of the American Heart Association*, *8*(17). https://doi.org/10.1161/jaha.119.012788
10. Baghdadi, N. A., Farghaly Abdelaliem, S. M., Malki, A., Gad, I., Ewis, A., & Atlam, E. (2023). Advanced machine learning techniques for cardiovascular disease early detection and diagnosis. *Journal of Big Data*, *10*(1). https://doi.org/10.1186/s40537-023-00817-1
11. Samanidis, G. (2024). Current challenges in diagnosis and treatment of cardiovascular disease. *Journal of Personalized Medicine*, *14*(8), 786. https://doi.org/10.3390/jpm14080786
12. Visco, V. (2021). Artificial intelligence as a business partner in cardiovascular precision medicine: An emerging approach for disease detection and treatment optimization. *Current Medicinal Chemistry*, *28*(32), 6569-6590. https://doi.org/10.2174/1875533xmtey3ntmax
13. Ekundayo, F., & Nyavor, H. (2024). AI-driven predictive analytics in cardiovascular diseases: Integrating big data and machine learning for early diagnosis and risk prediction. *International Journal of Research Publication and Reviews*, *5*(12), 1240-1256. https://doi.org/10.55248/gengpi.5.1224.3437
14. Zaman, Q., The Role of Artificial Intelligence in Early Disease Detection: Transforming Diagnostics and Treatment. Multidisciplinary Journal of Healthcare (MJH), 2024. 1(2): p. 43-54.
15. Harjai, S., & Khatri, S. K. (2019). An intelligent clinical decision support system based on artificial neural network for early diagnosis of cardiovascular diseases in rural areas. *2019 Amity International Conference on Artificial Intelligence (AICAI)*, 729-736. https://doi.org/10.1109/aicai.2019.8701237

16. Huang, J., Wang, J., Ramsey, E., Leavey, G., Chico, T. J., & Condell, J. (2022). Applying artificial intelligence to wearable sensor data to diagnose and predict cardiovascular disease: A review. *Sensors*, *22*(20), 8002. https://doi.org/10.3390/s22208002
17. Adedinsewo, D. A., Pollak, A. W., Phillips, S. D., Smith, T. L., Svatikova, A., Hayes, S. N., Mulvagh, S. L., Norris, C., Roger, V. L., Noseworthy, P. A., Yao, X., & Carter, R. E. (2022). Cardiovascular disease screening in women: Leveraging artificial intelligence and digital tools. *Circulation Research*, *130*(4), 673-690. https://doi.org/10.1161/circresaha.121.319876
18. Krittanawong, C., Zhang, H., Wang, Z., Aydar, M., & Kitai, T. (2017). Artificial intelligence in precision cardiovascular medicine. *Journal of the American College of Cardiology*, *69*(21), 2657-2664. https://doi.org/10.1016/j.jacc.2017.03.571
19. Mhamdi, L., Dammak, O., Cottin, F., & Dhaou, I. B. (2022). Artificial intelligence for cardiac diseases diagnosis and prediction using ECG images on embedded systems. *Biomedicines*, *10*(8), 2013. https://doi.org/10.3390/biomedicines10082013
20. Miller, R. J., Huang, C., Liang, J. X., & Slomka, P. J. (2022). Artificial intelligence for disease diagnosis and risk prediction in nuclear cardiology. *Journal of Nuclear Cardiology*, *29*(4), 1754-1762. https://doi.org/10.1007/s12350-022-02977-8
21. Athar, M. (2024). Potentials of artificial intelligence in familial hypercholesterolemia: Advances in screening, diagnosis, and risk stratification for early intervention and treatment. *International Journal of Cardiology*, *412*, 132315. https://doi.org/10.1016/j.ijcard.2024.132315
22. Tique, M. R., Araque, O., & Sanchez-Echeverri, L. A. (2024). Technological advances in the diagnosis of cardiovascular disease: A public health strategy. *International Journal of Environmental Research and Public Health*, *21*(8), 1083. https://doi.org/10.3390/ijerph21081083
23. Reddy, C. D., Van den Eynde, J., & Kutty, S. (2022). Artificial intelligence in perinatal diagnosis and management of congenital heart disease. *Seminars in Perinatology*, *46*(4), 151588. https://doi.org/10.1016/j.semperi.2022.151588
24. Singhal, S., & Kumar, M. (2022). A systematic review on artificial intelligence-based techniques for diagnosis of cardiovascular arrhythmia diseases: Challenges and opportunities. *Archives of Computational Methods in Engineering*, *30*(2), 865-888. https://doi.org/10.1007/s11831-022-09823-7
25. Al-Maini, M., Maindarkar, M., Kitas, G. D., Khanna, N. N., Misra, D. P., Johri, A. M., Mantella, L., Agarwal, V., Sharma, A., Singh, I. M., Tsoulfas, G., Laird, J. R., Faa, G., Teji, J., Turk, M., Viskovic, K., Ruzsa, Z., Mavrogeni, S., Rathore, V., … Suri, J. S. (2023). Artificial intelligence-based preventive, personalized and precision medicine for cardiovascular disease/stroke risk assessment in rheumatoid arthritis patients: A narrative review. *Rheumatology International*, *43*(11), 1965-1982. https://doi.org/10.1007/s00296-023-05415-1
26. Ghaffar Nia, N., Kaplanoglu, E., & Nasab, A. (2023). Evaluation of artificial intelligence techniques in disease diagnosis and prediction. *Discover Artificial Intelligence*, *3*(1). https://doi.org/10.1007/s44163-023-00049-5
27. Alizadehsani, R., Khosravi, A., Roshanzamir, M., Abdar, M., Sarrafzadegan, N., Shafie, D., Khozeimeh, F., Shoeibi, A., Nahavandi, S., Panahiazar, M., Bishara, A., Beygui, R. E., Puri, R., Kapadia, S., Tan, R., & Acharya, U. R. (2021). Coronary artery disease detection using artificial intelligence techniques: A survey of trends, geographical differences and diagnostic features 1991–2020. *Computers in Biology and Medicine*, *128*, 104095. https://doi.org/10.1016/j.compbiomed.2020.104095
28. Seetharam, K., Brito, D., Farjo, P. D., & Sengupta, P. P. (2020). The role of artificial intelligence in cardiovascular imaging: State of the art review. *Frontiers in Cardiovascular Medicine*, *7*. https://doi.org/10.3389/fcvm.2020.618849
29. Elvas, L. B., Nunes, M., Ferreira, J. C., Dias, M. S., & Rosário, L. B. (2023). AI-driven decision support for early detection of cardiac events: Unveiling patterns and predicting myocardial ischemia. *Journal of Personalized Medicine*, *13*(9), 1421. https://doi.org/10.3390/jpm13091421

30. Laudicella, R. (2021). Artificial neural networks in cardiovascular diseases and its potential for clinical application in molecular imaging. *Current Radiopharmaceuticals*, *14*(3), 209-219. https://doi.org/10.2174/18744729mta3dntiz4
31. Bouris, V., & Avgerinos, E. (2024). AI applications in cardiovascular disease diagnosis and management. *Advances in Medical Technologies and Clinical Practice*, 169-184. https://doi.org/10.4018/979-8-3693-4422-4.ch009
32. Chlorogiannis, D., Apostolos, A., Chlorogiannis, A., Palaiodimos, L., Giannakoulas, G., Pargaonkar, S., Xesfingi, S., & Kokkinidis, D. G. (2023). The role of ChatGPT in the advancement of diagnosis, management, and prognosis of cardiovascular and cerebrovascular disease. *Healthcare*, *11*(21), 2906. https://doi.org/10.3390/healthcare11212906
33. Nedadur, R., Wang, B., & Tsang, W. (2022). Artificial intelligence for the echocardiographic assessment of valvular heart disease. *Heart*, *108*(20), 1592-1599. https://doi.org/10.1136/heartjnl-2021-319725
34. Kwon, J., Kim, K., Eisen, H. J., Cho, Y., Jeon, K., Lee, S. Y., Park, J., & Oh, B. (2020). Artificial intelligence assessment for early detection of heart failure with preserved ejection fraction based on electrocardiographic features. *European Heart Journal - Digital Health*, *2*(1), 106-116. https://doi.org/10.1093/ehjdh/ztaa015
35. Batta, I., Patial, R., C Sobti, R., & K Agrawal, D. (2024). Computational biology in the discovery of biomarkers in the diagnosis, treatment and management of cardiovascular diseases. *Cardiology and Cardiovascular Medicine*, *8*(5). https://doi.org/10.26502/fccm.92920400
36. Upton, R., Mumith, A., Beqiri, A., Parker, A., Hawkes, W., Gao, S., Porumb, M., Sarwar, R., Marques, P., Markham, D., Kenworthy, J., O'Driscoll, J. M., Hassanali, N., Groves, K., Dockerill, C., Woodward, W., Alsharqi, M., McCourt, A., Wilkes, E. H., … Leeson, P. (2022). Automated Echocardiographic detection of severe coronary artery disease using artificial intelligence. *JACC: Cardiovascular Imaging*, *15*(5), 715-727. https://doi.org/10.1016/j.jcmg.2021.10.013